New hope for Tough-to-Treat testicular cancer: trial tests maintenance pill combo
NCT ID NCT06937866
Summary
This study is testing whether taking two oral drugs, zanzalintinib and etoposide, as long-term 'maintenance' therapy can help keep cancer from returning in patients with relapsed germ cell tumors (like testicular cancer). The goal is to see if this combination is safe and can extend the time patients live without their cancer progressing after they've already undergone very intensive, high-dose chemotherapy and a stem cell transplant. It is for patients whose cancer has come back and who have few other treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.